Medical Oncology| Volume 73, ISSUE 5, P1104-1109, May 2009

Download started.


Prevalence of Skeletal Complications and Their Impact on Survival of Hormone Refractory Prostate Cancer Patients in Japan


      Skeletal complications are a crucial factor in the quality of life and the prognosis of patients with hormone-refractory prostate cancer (HRPC); however, their true prevalence and impact on the prognosis remain largely unknown. In this study, we retrospectively investigated the prevalence of skeletal complications and survival of HRPC patients in a single Japanese institute.


      From 1990 to 2004, 151 patients with prostate cancer were estimated to have HRPC after androgen ablation therapy in a single institute. The medical records of the patients were reviewed for documentation of skeletal complications, and overall survival was calculated from the diagnosis of HRPC.


      At the diagnosis of HRPC, bone metastases and bone pain were observed in 83.8% and 44.7% of patients, respectively. During follow-up, 80.0% and 14.2% of patients experienced bone pain and bone fracture, respectively. Moreover, 74.2% and 43.9% of the patients received nonsteroidal anti-inflammatory drugs and opioids for bone pain, respectively, and 50.9% of the patients underwent radiotherapy for palliative pain control. A high score on the extent of disease observed on the bone scan and the presence of bone pain at the diagnosis of HRPC were independent prognostic factors on multivariate analysis (hazard ratio = 1.753 and 2.118, P = .033 and .007, respectively).


      Despite a small number of subjects, our retrospective survey demonstrated the high prevalence and mortality rate of skeletal complications in Japanese HRPC patients. Patients with bone pain at the diagnosis of HRPC had significantly poorer prognosis than those without.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Carlin B.I.
        • Andriole G.L.
        The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma.
        Cancer. 2000; 88: 2989-2994
        • Shahinian V.B.
        • Kuo Y.F.
        • Freeman J.L.
        • Goodwin J.F.
        Risk of fracture after androgen deprivation for prostate cancer.
        N Engl J Med. 2005; 352: 154-164
        • Parkin D.M.
        • Pisani P.
        • Ferlay J.
        Global cancer statistics.
        CA Cancer J Clin. 1999; 49: 33-64
        • Kung H.C.
        • Hoyert D.L.
        • Xu J.
        • Murphy S.L.
        Deaths: Final data for 2005.
        Natl Vital Stat Rep. 2008; 56: 1-124
      1. Center for Cancer Control and Information Services, National Cancer Center, Japan. Vital Statistics of Japan (Ministry of Health, Labour & Welfare).

        • Naito S.
        • Tsukamoto T.
        • Koga H.
        • et al.
        Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: A multicenter phase II trial in Japan.
        Jpn J Clin Oncol. 2008; 38: 365-372
        • Shimazui T.
        • Kawai K.
        • Miyanaka N.
        • et al.
        Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: A retrospective comparative study with weekly docetaxel alone.
        Jpn J Clin Oncol. 2007; 37: 603-608
        • Soloway M.S.
        • Hardeman S.W.
        • Hickey D.
        • et al.
        Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan.
        Cancer. 1988; 61: 195-202
        • Saad F.
        • Gleason D.M.
        • Murray R.
        • et al.
        • Zoledronic Acid Prostate Cancer Study Group
        A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
        J Natl Cancer Inst. 2002; 94: 1458-1468
        • Berruti A.
        • Tucci M.
        • Mosca A.
        • et al.
        Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.
        Br J Cancer. 2005; 93: 633-638
        • Rades D.
        • Stalpers L.J.
        • Veninga T.
        • Rudat V.
        • Schulte R.
        • Hoskin P.J.
        Evaluation of functional outcome and local control after radiotherapy for metastatic spinal cord compression in patients with prostate cancer.
        J Urol. 2006; 175: 552-556
        • Bercovitch M.
        • Adunsky A.
        Patterns of high-dose morphine use in a home-care hospice service.
        Cancer. 2004; 101: 1473-1477
        • Berruti A.
        • Dogliotti L.
        • Bitossi R.
        • et al.
        Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline.
        J Urol. 2000; 164: 1248-1253
        • Oefelein M.G.
        • Ricchiuti V.
        • Conrad W.
        • Resnick M.I.
        Skeletal fractures negatively correlate with overall survival in men with prostate cancer.
        J Urol. 2002; 168: 1005-1007
        • Oefelein M.G.
        • Ricchuiti V.
        • Conrad W.
        • et al.
        Skeletal fractures associated with androgen suppression induced osteoporosis: The clinical prevalence and risk factors for the patients with prostate cancer.
        J Urol. 2001; 166: 1724-1728